Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

1 May 2012

Abstract excerpt

BACKGROUND: Trastuzumab and pertuzumab target the Human Epidermal growth factor Receptor 2 (HER2). Combination therapy has been shown to provide enhanced antitumour activity; however, the downstream signalling to explain how these drugs mediate their response is not clearly understood. METHODS: Transcriptome profiling was performed after 4 days of trastuzumab, pertuzumab and combination treatment in human ovarian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy-induced cardiotoxicity and mitigation
Share to HER2/EGFR in Cancer Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22549178
DOI: 10.1038/bjc.2012.176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerPMID 22549178Read ↗

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenograftsSemantic proximity Read ↗

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.Semantic proximity Read ↗

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer TherapySemantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression LevelsSemantic proximity Read ↗

The hallmarks of ovarian cancer: proliferation and cell growthSemantic proximity Read ↗

Crosstalk between YAP and HER2 drives HER2-mediated breast cancer progression via synergistic growth factor upregulationSemantic proximity Read ↗

Sequenced Combinations of Cisplatin and Selected Phytochemicals Towards Overcoming Drug Resistance in Ovarian Tumour ModelsSemantic proximity Read ↗

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity Read ↗

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingSemantic proximity Read ↗

Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.